ALL PRESENTATIONS ARE 100% LATEX-FREE

PrWEZLANA™ ustekinumab injection

DOSING GUIDE

SAME FORMAT AND DOSES AVAILABLE AS ORIGINATOR USTEKINUMAB (STELARA®)[1,2]

Single-use prefilled syringe

45 and 90 mg: for subcutaneous injection

FORMATS	DIN	BARCODE
45 mg	TBD	TBD
90 mg	TBD	TBD

Single-use vial

45 mg: for subcutaneous injection

130 mg: for intravenous injection

FORMATS	DIN	BARCODE
45 mg	TBD	TBD
130 mg	TBD	TBD

Please consult the Product Monograph for complete information and administration instructions.

Amgen Entrust™ Patient Support Services provides personalized support for both you and your patients every step of the way, including injection training and patient assistance.

Call: 1-877-936-2735 | **Email:** wezlana@oneenliven.ca

AMGEN Entrust™ Enliven®

Scan the QR code or direct your patients to www.WEZLANA.ca for a step-by-step video on how to self-inject with a prefilled syringe.

Indications have been granted on the basis of similarity between WEZLANA™ and the reference biologic drug STELARA®.
WEZLANA™ (ustekinumab injection) is indicated in adults for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
See reverse for full list of indications.

DIN: drug identification number; I.V.: intravenous; SC: subcutaneous
*Clinical significance is unknown.

SAME INDICATIONS AND DOSAGE AS ORIGINATOR USTEKINUMAB (STELARA®)[1,2]

	INDICATIONS	DOSAGE
	**CD** The treatment of adult patients with moderately to severely active CD, who have had an inadequate response, loss of response to, or were intolerant to either immunomodulators or one or more TNF-α antagonists, or have had an inadequate response, intolerance or demonstrated dependence on corticosteroids.	**INDUCTION PHASE:** recommended dose ~6 mg/kg •≤ 55 kg: 260 mg •55 kg to ≤ 85 kg: 390 mg •85 kg: 520 mg **MAINTENANCE PHASE:** recommended 90 mg at week 8 following I.V. induction dose with subsequent doses given every 8 weeks and thereafter†
	UC The treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.	
	**PsO** The treatment of chronic moderate to severe PsO who are candidates for phototherapy or systemic therapy.	Week 0=45 mg Week 4=45 mg Every 12 weeks thereafter=45 mg • >100 kg: 90 mg
	PED PsO The treatment of chronic moderate to severe PsO in pediatric patients (children and adolescents) from 6 to 17 years of age, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.	Week 0, 4, and every 12 weeks thereafter • < 60 kg: 0.75 mg/kg* • ≥ 60 kg to ≤ 100 kg: 45 mg • > 100 kg: 90 mg
	**PsA** The treatment of adult patients with active PsA. WEZLANA can be used alone or in combination with MTX.	Week 0=45 mg Week 4=45 mg Every 12 weeks thereafter=45 mg >100 kg: 90 mg

Please see the Product Monograph for complete dosing and administration information.

CD: Crohn's disease; I.V.: intravenous; UC: ulcerative colitis; PsO: psoriasis ; PsA: psoriatic arthritis
*To calculate the volume of injection, use the following formula: body weight (kg) x 0.0083 (mL/kg).
†In some patients subsequent doses may be given every 12 weeks thereafter (can be adjusted to every 8 weeks in case of inadequate response.

Please consult the Product Monograph XXXXXX for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.
The Product Monograph can also be obtained by calling Amgen Medical Information at 1-866-502-6436.

REFERENCES:
1. WEZLANA™ Product Monograph. Amgen Canada. DATE.
2. STELARA® Product Monograph. Janssen Inc. April 5, 2023.

AMGEN® BIOSIMILARS

REVIEWED BY PAAB

MEMBER OF INNOVATIVE MEDICINES CANADA